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Background/Purpose: Children with high-risk neuroblastoma (NBL) have high-mortality rates 
and undergo complex, multi-modal therapy. They may be subject to fragmented care among 
different providers and institutions, which has been associated with worse outcomes for various 
adult cancers. These patients may also experience significant travel burden in accessing 
appropriately equipped facilities. We hypothesize that fragmented care for pediatric NBL 
patients is associated with inferior outcomes compared to treatment consolidated at one location. 
 
Methods: Paper and electronic records for pediatric NBL patients having received ≥1 bone 
marrow transplant at our institution from 1990-2018 were manually reviewed. Variables 
collected include demographics, diagnostic and treatment characteristics, complications, and 
relapse and survival outcomes. Fragmented care is defined by treatment occurring at >1 
institution and grouped according to 2 institutions vs. >2 institutions. Distances are calculated 
using Google Maps. Fisher’s exact and Kruskal-Wallis tests were used to compare patients 
receiving fragmented versus consolidated care. Unadjusted overall survival (OS) was estimated 
using the Kaplan-Meier method, and differences in OS between groups were tested using the 
log-rank test. 
 
Results: We extracted data from 128/148 patients. The most common reasons for exclusion 
included incomplete medical records (n=9) and BMT for relapse/recurrence only (n=8). 103 
patients experienced fragmented care, with 18 of them being treated at 3+ facilities. More 
patients with consolidated care were above the 75th percentile for distance traveled to 
chemotherapy and surgery, while more patients with 3+ facilities were above the 75th percentile 
for distance traveled to BMT and immunotherapy (all p<0.01). On univariate analysis, neither 
fragmented care group was associated with mortality (p>0.05). Diagnosis in earlier decades, 
particular chemotherapy protocols, enrollment on a clinical trial (compared to being treated 
according to its guidelines), and increased distance to BMT were all significantly associated with 
increased mortality (p<0.05). Only diagnostic year and distance to BMT remained significantly 
associated with OS on multivariate analysis. 
 
Conclusion: In the largest institutional analysis of fragmented care for pediatric NBL patients, 
we demonstrate no association between degree of fragmented care or travel distance and OS or 
relapse rates. These findings may be critical to those living far removed from appropriate 
treatment. Further research and interventions should explore lower-risk disease and aim to 
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 Treatment of pediatric cancer is frequently complex and multimodal, often delivered 
through enrollment on or according to clinical trial protocols.1,2 Accordingly, the American 
Academy of Pediatrics (AAP) recommends that pediatric cancer patients receive care at 
specialized pediatric cancer centers that have the expertise and resources necessary to deliver 
trial-based therapy safely and effectively.3 For many pediatric cancer patients, consistent 
evidence demonstrates improved clinical and survival outcomes associated with receipt of care at 
these specialized centers.4-8 Many of these centers are members of the Children’s Oncology 
Group (COG), a National Cancer Institute-sponsored clinical trials group organized in 2000 to 
ensure regionalized, multidisciplinary treatment.9 Recommendations to deliver care at COG 
institutions, in addition to advanced therapeutic innovations, have led to survival rates now 
exceeding 80% for pediatric cancer patients.10 
 Over 90% of pediatric cancer patients in the US are treated at COG-member institutions, 
but many may receive care from more than one facility.11 In these circumstances, there is 
concern for a lack of effective communication and coordination among providers. Such 
fragmented care for adult oncology patients, following major cancer surgery or otherwise, has 
been associated with increased healthcare costs, more complications, and decreased survival.12-17 
Numerous studies have also demonstrated improved outcomes for several malignancies 
associated with use of multidisciplinary tumor conferences (MDCs), which allow multiple 
providers to convene in one setting to discuss the treatment plan for a given patient.18-21 
Together, these results create an argument for centralizing and coordinating pediatric cancer care 
within single, specialized institutions. In addition to improved clinical outcomes, such 
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coordinated oncologic care has the benefit of reducing anxiety and unnecessary responsibility for 
family members.22 
 Despite certain advantages of consolidated care, reducing fragmented oncologic care for 
pediatric cancer patients constitutes a significant challenge. The 194 COG-member institutions in 
the US remain concentrated in major urban environments.11 This is problematic given that 
approximately 20% of American families live in rural communities far removed from COG-
member institutions.23 Additionally, as pediatric cancer treatment grows in complexity with such 
treatments as immunotherapy, not every specialized facility is equipped to offer all facets of 
treatment. As such, pediatric cancer patients and their families must frequently travel significant 
distances in the hopes of receiving appropriately consolidated treatment. For adult cancer 
patients, some studies have shown that those who live and travel further to treatment may present 
with later stage disease, receive different treatments than their closer counterparts, and 
experience worsened survival outcomes.24 However, comparably sparse literature exists 
examining the effect of fragmented care and travel burden for pediatric cancer patients. 
 Populations with specific cancers may be at higher risk for adverse outcomes associated 
with fragmented care delivery. Neuroblastoma (NBL) is the most common solid extracranial 
pediatric malignancy and presently accounts for nearly 15% of childhood cancer deaths.25 It is a 
tumor derived from neural crest sympthoadrenal lineage progenitor cells and has a highly 
heterogeneous clinical course.21 While it can develop anywhere within the sympathetic nervous 
system, the adrenal gland is the most common primary site, followed by other retroperitoneal and 
thoracic locations.25 Beginning in 2009, NBL patients are classified as either low, intermediate, 
or high-risk based on numerous pathological and clinical factors, as outlined in the International 
Neuroblastoma Risk Group Staging System (INRGSS).26 High-risk patients typically receive 
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complex treatment regimens consisting of chemotherapy, surgical resection, radiation, high-dose 
autologous peripheral blood stem cell (PBSC) transplantation, and immunotherapy.21 Because 
effective PBSC transplantation and immunotherapy is only offered at few COG-member 
institutions, high-risk NBL patients may be particularly susceptible to fragmented care.  
 In this study, we sought to use an institutional series of neuroblastoma patients whose 
treatment course has involved at least one bone marrow transplantation at Duke University to 
elucidate and better understand the effects of fragmented care and travel distance on clinical and 
survival outcomes. We hypothesize that patients whose care is split between more institutions 





 We conducted a retrospective analysis of pediatric NBL patients diagnosed from 1990-
2017 who received multimodality therapy and at least one bone marrow transplantation (BMT) 
at Duke University. Paper and electronic medical records were reviewed by AT and MA to 
extract relevant variables into a standardized Excel spreadsheet. Specifically, we examined all 
relevant discharge summaries, outpatient notes, flowsheets, correspondences, operation notes, 
and pathology and radiology reports. Ethical approval for this study was granted by the Duke 
University and University of North Carolina – Chapel Hill Institutional Review Boards. 
Informed consent was not required. All collected patient data and protected health information 





Study Population and Case Selection 
The study population included any patients aged 0-18 with histologically confirmed NBL 
treated with at least one BMT at Duke from 1990-2017. This patient population was selected 
because the pediatric BMT team at Duke has maintained detailed clinical records of all patients 
seen on their service, including NBL patients. Patients were excluded if they had BMT only 
subsequent to relapsed NBL or had incomplete or unavailable medical records. Additional 
exclusion criteria included incorrect diagnoses, low-risk disease at diagnosis, and any 
international treatment prior to referral to Duke.  
 
Study Variables 
A comprehensive database of all information related to patient demographics, diagnosis, 
treatment, and outcomes was compiled. The variables utilized for analysis in this study are 
reported here.  
Diagnosis date was defined as the date of histologically confirmed NBL. Demographic 
variables collected included age at diagnosis, sex, race/ethnicity, insurance status (defined as 
public payer, private, or both), and home address.  
Disease-related variables included the primary anatomic site of the tumor, size of the 
largest dimension, histologic grade (defined as favorable or unfavorable histology), amplification 
status of the N-MYC gene, DNA ploidy as a continuous variable, and the presence of any image-
defined risk factors (IDRFs). The INRG task force has identified 20 IDRFs based on anatomic 
location of the primary tumor and extent of involvement into adjacent vasculature, organs, and/or 
body cavities.26 Importantly, IDRFs were not incorporated into the INRGSS until 2009, meaning 
many patient records did not mention presence or absence of IDRFs. In these instances, available 
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radiologic reports were reviewed by AT and MA and classified according to the task force 
report.26 Because of the changes in NBL staging in recent decades, both INRG risk groups and 
traditional INSS staging was reported. Additionally, the diagnostic method of confirmation or 
biopsy type was also recorded. 
 Variables related to BMT, surgery, chemotherapy, radiation, and immunotherapy were 
also collected. For BMT, we recorded the number of BMTs received and the presence or absence 
of any major complications, defined as any complication requiring invasive intervention or 
resulting in serious disability or death. For surgery, we recorded whether patients received 
surgical resection, days to surgery from diagnosis, complete or incomplete resection, tumor 
margin status, length of stay (days) for the surgical admission, the presence of any major surgical 
complications and/or unplanned readmissions, and the total number of surgeries conducted for 
the primary tumor (including the initial surgical biopsy if performed). For chemotherapy, we 
recorded the days to the first cycle from diagnosis, whether patients were enrolled on or treated 
only according to a given clinical trial protocol, the number of cycles received, and the presence 
of any major complications. For radiation, we recorded the days to radiation from diagnosis, the 
modality of radiation received (involved field, proton beam, MIBG, TBI), dose, and total days of 
radiation received. We also reported whether patients received immunotherapy, whether any 
thrombotic complications resulted during treatment, how many central lines were placed, and the 
number of line infections per patient.  
 The facility location of each treatment modality was reported and used to stratify patients 
into either consolidated or fragmented care cohorts. Consolidated care was defined as all cancer-
specific treatments occurring at Duke University. The fragmented cohort was further stratified 
into 2 facilities or >2 facilities involved in cancer-specific treatments. Importantly, we were not 
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able to assess all other clinical visits, such as PCP or acute care visits. These were therefore not 
factored into the definitions of consolidated or fragmented care. We also reported whether each 
facility involved in cancer-specific treatment was a COG-member institution, and a variable was 
created to determine whether each patient had all treatment or some treatment at COG-member 
institutions. Distances to each treatment facility were calculated as the driving distance between 
each patient’s home postal code and the postal code of the treatment facility using Google Maps.  
 
Data Analysis 
 The consolidated and two fragmented care groups were first compared by demographic, 
disease-related, and treatment-related characteristics using descriptive statistics (means and 
standard deviations, median and IQR, or counts and percentages where appropriate). The 
presence of any major and minor complications were also analyzed and stratified by consolidated 
or fragmented groups. Fisher’s exact test was used for categorical variables, and Kruskall-Wallis 
tests were used for continuous variables.  
 The primary outcome was overall survival (OS), defined as death due to any cause. The 
time to event was defined as the time from date of diagnosis to the date of death or last follow-
up. Secondary outcomes included the presence of relapse occurring after documented completion 
of the initial treatment course. Time to event distributions for OS and relapse were estimated 
with the Kaplan-Meier method and compared across the 3 study groups. The univariate 
significance of fragmented care and other patient, disease, and treatment characteristics on both 
OS and relapse was assessed using Cox proportional hazards modeling. The year of diagnosis 
was divided into 3 decades to approximate the timing and availability of various well-known 
clinical trials for neuroblastoma treatment. The mean for days from diagnosis to surgery was 
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skewed as a result of some patients receiving surgical resection as a part of the diagnostic work-
up, as compared to those receiving surgery later in the treatment course. As such, a variable 
dividing patients into those receiving surgery before or after initiation of chemotherapy was 
used. In analyzing the effect of particular clinical trial protocols, we used the most well-known 
and common among this dataset. Finally, the distance to chemotherapy was chosen to 
approximate the shorter distance many patients traveled in receiving local therapy, and the 
distance to BMT was chosen to estimate the effect of long-distance travel for some patients 
during their treatment course. Variables that were significant in univariate analysis and with 
clinical relevance were included in a multivariate regression model for both OS and relapse. Not 




 We identified 148 children with NBL treated at Duke University for BMT diagnosed 
from 1990 – 2017. Of these, 128 were deemed eligible and included in the final analysis. The 
most common reasons for exclusion included BMT for relapse/recurrence only (n=8), incomplete 
medical records (n=9), one patient with an incorrect diagnosis, one patient with low-risk disease, 
and one patient who received all initial treatment outside the United States. Patients hailed from 
and were treated at facilities in eight different states (Figure 1). 
 As seen in Table 1, 103/128 (80.4%) of patients experienced fragmented care. Of these, 
85/103 (82.5%) were treated at 2 separate facilities, while 18/103 (17.5%) were treated at 3+ 
facilities. Mean patient age was 3.5 years at diagnosis, and those with 2 treatment facilities were 
older on average (3.9 ± 2.52 years, p=0.01). No significant differences were identified between 
consolidated and fragmented groups based on sex, race, or insurance. Those with 3+ treatment 
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facilities were more likely to receive only some of their care at COG-member institutions (22.2% 
for 3+ facilities, 4.7% for 2 facilities, p=0.02). Regarding disease-level characteristics, no 
significant differences were identified based on primary tumor site, histology, N-MYC status, 
presence of IDRFs, or INSS stage.  
 Patients treated at 3+ facilities were more likely to have an increased length of stay for 
the surgical admission compared to those with 2 facilities or consolidated care (mean 7.2 days 
for 3+ facilities, 6.2 days for 2 facilities, 5.4 days for consolidated care, p=0.04). A significant 
difference was also noted between groups for the mean number of central lines a patient had 
placed (mean 4.1 lines for 3+ facilities, 3.2 lines for 2 facilities, 4.4 lines for consolidated care, 
p=0.002). Patients receiving care at 3+ facilities were more likely to receive immunotherapy 
(55.6% for 3+ facilities, 25.9% for 2 facilities, 44.0% for consolidated care, p=0.03). Significant 
differences were noted for distance traveled to each therapy between groups. More patients with 
consolidated care were above the 75th percentile for distance traveled to chemotherapy and 
surgery, while more patients with 3+ facilities were above the 75th percentile for distance 
traveled to BMT and immunotherapy (all p<0.01). Finally, those with consolidated care were 
more likely to have a major complication during treatment, specifically a major BMT-related 
complication (p=0.01, p=0.02, respectively) (Table 2). 
 Kaplan-Meier analysis demonstrated significant differences between the three study 
groups for relapse-free survival (log-rank p=0.0251) but no significant difference for OS (log-
rank p=0.025) (Figure 2). On univariate analysis, neither fragmented care group was associated 
with mortality (p>0.05 for both groups). Diagnosis in earlier decades, particular chemotherapy 
protocols, enrollment on a clinical trial (compared to being treated according to its guidelines), 
and increased distance to BMT were all significantly associated with increased mortality 
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(p<0.05) (Table 3).  Being treated at 3+ facilities was associated with worsened relapse-free 
survival (HR 2.583, 95% CI: 1.113 - 5.990, p=0.027). Additionally, diagnosis in earlier decades, 
enrollment on a clinical trial (compared to being treated according to its guidelines), and 
increased distance to BMT were all significantly associated with increased rates of relapse 
(p<0.05) (Table 4). On multivariate analysis, only diagnosis in earlier decades and increased 
travel distance to BMT remained significantly associated with worsened mortality (p=0.024 and 
p=0.043, respectively). For relapse, only diagnosis in earlier decades remained significantly 




 In this institutional study of NBL patients treated with at least one BMT, we 
hypothesized that those patients whose care is fragmented between multiple institutions and who 
have had to travel further for each treatment would experience increased rates of relapse and 
mortality. Our results demonstrate that consolidated care does not necessarily confer long-term 
survival advantage for high-risk NBL patients, but that traveling further to receive BMT is 
associated with increased relapse and mortality. Increasingly, guidelines recommend 
consolidating and centralizing care for oncology patients.27-31 However, our findings constitute 
an important consideration for pediatric cancer patients and their families who must overcome 
significant travel burdens to receive such highly specialized, consolidated care.27-31  
 With no apparent survival advantage based on consolidated care, many families may 
elect to receive as much treatment as possible closer to home and avoid a significant travel 
burden. As such, it is critical to ensure that rural facilities are adequately equipped to handle the 
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complexity associated with high-risk NBL, regardless of their COG membership status. There is 
a well-established relationship between better surgical outcomes and higher hospital volume for 
adult cancers of the colon and rectum, esophagus, adrenal glands, and thyroid gland.32-37 
However, many such high-volume hospitals are located in metropolitan settings, leaving certain 
rural facilities without the necessary volume and expertise for effective oncologic surgery. 
Markin et al. demonstrated that complex oncologic surgical resections have higher mortality in 
rural hospitals as compared to specialty centers.38 Similarly, Lidsky et al. demonstrated that 
patients undergoing pancreaticoduodenectomy for pancreatic cancer experience improved 
outcomes in urban high-volume hospitals despite an increased travel burden.39 Yet, similar 
volume-outcome relationships for pediatric surgery have been challenged, as Gutierrez et al. 
found no correlation between hospital volume and survival outcomes for pediatric patients with 
Wilms tumor or neuroblastoma.40 Ultimately, our study supports the findings by Gutierrez et al. 
and may indicate that pediatric cancer patients and their families may achieve equitable 
outcomes by opting for care closer to home. 
 Interestingly, our results showed that increased travel distance to BMT was associated 
with poorer relapse and survival outcomes. However, the distance traveled to chemotherapy, 
used as a proxy for the shorter distance many patients travel to receive most of their care, was 
not significant. Several studies have shown worsened outcomes for adult cancer patients based 
on increased travel distance.24,41,42 There has been comparably little research in pediatric cancer, 
but some studies have demonstrated no survival detriment from increased travel distance.43-46 
Those patients that traveled furthest to BMT in our dataset were predominately from Alabama, 
Georgia, and Florida and were diagnosed in the 1990s prior to the institution of more local 
specialized BMT options. As such, our results may be more indicative of the poorer survival in 
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the 1990s as compared to recent years, even though diagnostic time-period was adjusted for in 
the multivariate model. Additionally, it may be that the sickest patients were referred to Duke for 
BMT instead of local facilities because of perceived expertise in complex pediatric cancer 
management, thus skewing mortality outcomes.  
Fragmentation in our study was largely driven by patients traveling to Duke for BMT or 
to other highly specialized facilities for complex immunotherapy or unique radiation modalities, 
such as proton beam therapy or MIBG therapy. These reasons likely explain the significant 
differences in distance between each group. Such treatments are generally able to be delivered 
safely and effectively only at select large institutions in the US, and avoiding fragmented care for 
patients who require them may be impossible. Several studies have demonstrated that providing 
autologous BMT and proton beam therapy to pediatric patients may be cost-effective, prompting 
consideration for establishing more facilities capable of delivering such treatments to rural 
patients.47,48 Despite supposed cost-effectiveness, however, the total costs for such therapies are 
exorbitant and typically too prohibitive for smaller, rural centers to consider funding, particularly 
given the small volume of requisite patients they might see.47,48 As these therapies grow to 
become treatment mainstays for many malignancies, the high price of expansion and 
consolidation must be considered for families seeking to avoid increased travel and fragmented 
care. 
 Importantly, most patients in this study received all of their treatment at COG-member 
institutions, regardless of fragmented versus consolidated care. Because of the extensive 
resources and expertise available at such institutions, all patients likely received high-quality 
care and any potential effects of fragmentation may have been mitigated. The COG has 
significantly expanded its reach since its inception in 2000, meaning even those families living in 
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rural settings may still access high-quality, standardized care.11 Our results do not demonstrate 
any disparity among patients receiving care at COG-member institutions based on residence, age, 
or other socioeconomic factors. Other studies have similarly noted that children are equally 
treated at COG facilities regardless of race, place of residence, or insurance status.49,50 However, 
these studies also note that increasing age is associated with a decreased likelihood of treatment 
at appropriate pediatric cancer centers, particularly for adolescents aged 15-19.49,50 Because 
neuroblastoma is typically seen in younger children, these findings are less concerning but merit 
important consideration for older NBL patients. 
 Improvements in survival for higher-risk NBL patients, despite the low rates compared to 
other pediatric cancers, can also be attributed to clinical trial-directed therapy. Most patients in 
our study were either enrolled on or treated according to risk-appropriate clinical trials. Several 
studies have noted widely variable enrollment on clinical trials for pediatric cancer patients, and 
myriad reasons exist for why patients may not be treated according to trial guidelines.51-53 The 
most common reasons for non-trial enrollment were lack of trial availability, physician decision, 
Hispanic race, and increased distance to the treating center.51-53 Our study did not assess the 
effect of distance on trial enrollment, but there was no significant difference between fragmented 
and consolidated groups based on trial enrollment status. With univariate analysis, those enrolled 
on a trial experienced higher rates of mortality than those simply treated according to trial 
guidelines. This was not assessed in multivariate analysis due to excess amount of missing data. 
However, it may be that those enrolled on a trial would not experience as much individualized 
treatment when it may be necessary. Additionally, physicians may seek out more experimentally-
rigorous trials on which to enroll the sickest patients. 
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 For rare childhood cancers such as NBL, large national databases provide the strength of 
increased sample sizes for analysis. However, such databases often lack the requisite data 
granularity, here defined as the level of detail and comprehensiveness of available patient and 
tumor-related variables, to conduct more in-depth analyses.54 Our study is strengthened by the 
granular detail achieved with manual chart review as compared to utilization of large national 
databases. We were able to collect and create a comprehensive database of relevant 
demographic, clinical, treatment-related, and outcome information for our institutional series of 
higher-risk NBL patients. 
However, our findings must interpreted in light of several limitations. The first is the 
small sample size inherent to single-institution analyses. However, high-risk NBL is a rare 
disease and even national databases may lack sufficient sample sizes and statistical power. 
Secondly, we were limited by the incompleteness of portions of available medical records. 
Frequently, adequate information about treatments offered at other institutions was lacking from 
discharge summaries, outpatient notes, and correspondences. However, this challenge is also 
indicative of the potential harms of fragmented care when providers and institutions 
communicate incompletely. We also chose to examine where each treatment was offered but 
could not track each hospitalization or if additional outpatient or ER visits occurred at additional 
institutions. With more complete records, a more comprehensive picture of the degree of 
fragmentation might be gleaned. Finally, while our study suggests that fragmented care and 
travel distance do not significantly affect survival for high-risk NBL patients, survival rates were 
poor among the entire cohort. Any potentially significant survival effects may have been 





 Our retrospective, single-institution study examining high-risk NBL patients suggests that 
oncologic care fragmented among multiple institutions is not associated with increased rates of 
relapse or mortality, which runs counter to increasing recommendations to consolidate and 
centralize cancer care. These results are critical for pediatric cancer patients and their families, 
who may live far removed from specialized pediatric cancer centers and would otherwise face 
significant financial and psychosocial stress associated with travel. It remains important to 
ensure that patients are treated at institutions, COG-members or otherwise, that are capable of 
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Figure 1: Heat Map Showing Locations of Referred Patients and Treating Facilities 
24 
 
















Year of Diagnosis     0.19 
1990-1999 41 (32.0%) 6 (24.0%) 30 (35.3%) 5 (27.8%)  
2000-2009 51 (39.8%) 7 (28.0%) 36 (42.4%) 8 (44.4%)  
2010-2017 36 (28.1%) 12 (48.0%) 19 (22.4%) 5 (27.8%)  
Age* 3.5 (2.41) 2.5 (1.58) 3.9 (2.52) 3.1 (2.45) 0.01 
Sex     0.82 
Male 83 (64.8%) 16 (64.0%) 54 (63.5%) 13 (72.2%)  
Female 45 (35.2%) 9 (36.0%) 31 (36.5%) 5 (27.8%)  
Race     0.17 
White 97 (75.8%) 16 (64.0%) 65 (76.5%) 16 (88.9%)  
African-American 24 (18.8%) 8 (32.0%) 15 (17.6%) 1 (5.6%)  
Other 4 (3.1%) 0 (0.0%) 3 (3.5%) 1 (5.6%)  
Insurance     0.12 
Public 41 (32.0%) 11 (44.0%) 27 (31.8%) 3 (16.7%)  
Private 74 (57.8%) 11 (44.0%) 51 (60.0%) 12 (66.7%)  
Both 7 (5.5%) 1 (4.0%) 4 (4.7%) 2 (11.1%)  
COG Facility Status     0.02 
Some treatment 8 (6.3%) 0 (0.0%) 4 (4.7%) 4 (22.2%)  
All treatment 120 (93.8%) 25 (100.0%) 81 (95.3%) 14 (77.8%)  
Primary Tumor Site     0.69 
Adrenal 92 (71.9%) 18 (72.0%) 61 (71.8%) 13 (72.2%)  
Retroperitoneal 20 (15.6%) 4 (16.0%) 13 (15.3%) 3 (16.7%)  
Mediastinum 7 (5.5%) 2 (8.0%) 5 (5.9%) 0 (0.0%)  
Paraspinal 4 (3.1%) 0 (0.0%) 3 (3.5%) 1 (5.6%)  
Other 2 (1.6%) 0 (0%) 1 (1.2%) 1 (5.6%)  
Histological Favorability     1.00 
Favorable 2 (1.6%) 0 (0.0%) 2 (2.4%) 0 (0.0%)  
Unfavorable 71 (55.5%) 16 (64.0%) 45 (52.9%) 10 (55.6%)  
Unknown 55 (43.0%) 9 (36.0%) 38 (44.7%) 8 (44.4%)  
N-Myc Status     0.82 
Non-Amplified 43 (33.6%) 10 (40.0%) 27 (31.8%) 6 (33.3%)  
Amplified 45 (35.2%) 8 (32.0%) 30 (35.3%) 7 (38.9%)  
Unknown 40 (31.3%) 7 (28.0%) 28 (32.9%) 5 (27.8%)  
IDRFs     0.30 
No 28 (21.9%) 6 (24.0%) 20 (23.5%) 2 (11.1%)  
Yes 75 (58.6%) 15 (60.0%) 45 (52.9%) 15 (83.3%)  
Unknown 25 (19.5%) 4 (16.0%) 20 (23.5%) 1 (5.6%)  
Tumor Diagnostic Confirmation Method     0.01 
Surgical Resection 22 (17.2%) 0 (0.0%) 20 (23.5%) 2 (11.1%)  
Open Biopsy Only 39 (30.5%) 10 (40.0%) 21 (24.7%) 8 (44.4%)  
Percutaneous/Needle Biopsy 9 (7.0%) 2 (8.0%) 7 (8.2%) 0 (0.0%)  
Bone Marrow Biopspy     0.31 
No 2 (1.6%) 0 (0.0%) 1 (1.2%) 1 (5.6%)  
Yes 116 (90.6%) 25 (100.0%) 75 (88.2%) 16 (88.9%)  
 Unknown 10 (7.8%) 0 (0.0%) 9 (10.6%) 1 (5.6%)  
25 
 
INSS Stage     0.31 
Stage 2B 1 (0.8%) 0 (0.0%) 1 (1.2%) 0 (0.0%)  
Stage 3 17 (13.3%) 4 (16.0%) 13 (15.3%) 0 (0.0%)  
Stage 4 97 (75.8%) 19 (76.0%) 61 (71.8%) 17 (94.4%)  
Stage 4S 2 (1.6%) 0 (0.0%) 1 (1.2%) 1 (5.6%)  
Stage D 11 (8.6%) 2 (8.0%) 9 (10.6%) 0 (0.0%)  
Surgery Performed 121 (94.5%) 23 (92.0%) 81 (95.3%) 17 (94.4%) 0.84 
Days to Surgery from Diagnosis* 113.6 (65.85) 130.0 (24.03) 105.3 (64.80) 129.4 (98.60) 0.26 
Complete Resection     0.06 
No 36 (28.1%) 10 (40.0%) 19 (22.4%) 7 (38.9%)  
Yes 32 (25.0%) 2 (8.0%) 24 (28.2%) 6 (33.3%)  
Unknown 60 (46.9%) 13 (52.0%) 42 (49.4%) 5 (27.8%)  
Surgical Margins     0.26 
No 28 (21.9%) 8 (32.0%) 17 (20.0%) 3 (16.7%)  
Yes 29 (22.7%) 5 (20.0%) 16 (18.8%) 8 (44.4%)  
Unknown 71 (55.5%) 12 (48.0%) 52 (61.2%) 7 (38.9%)  
Surgery Length of Stay (Days)* 6.0 (4.40) 5.4 (5.75) 6.2 (3.75) 7.2 (3.19) 0.04 
Readmission Following Surgery 6 (4.7%) 1 (4.0%) 4 (4.7%) 1 (5.6%) 0.81 
Number of Central Lines Placed* 3.5 (1.40) 4.4 (1.73) 3.2 (1.16) 4.1 (1.31) 0.002 
Central Line Infection 87 (68.0%) 21 (84.0%) 55 (64.7%) 11 (61.1%) 0.34 
Number of Line Infections* 1.2 (1.09) 1.5 (0.98) 1.1 (1.12) 1.2 (1.09) 0.11 
Days to Chemotherapy from Diagnosis* 6.6 (6.97) 5.2 (4.80) 7.3 (7.88) 5.0 (4.34) 0.44 
Treatment Protocol     0.19 
ANBL0532 28 (21.9%) 6 (24.0%) 18 (21.2%) 4 (22.2%)  
ANBL12P1 7 (5.5%) 5 (20.0%) 2 (2.4%) 0 (0.0%)  
CCG 3891 10 (7.8%) 1 (4.0%) 6 (7.1%) 3 (16.7%)  
COG A3961 2 (1.6%) 1 (4.0%) 1 (1.2%) 0 (0.0%)  
COG A3973 31 (24.2%) 5 (20.0%) 22 (25.9%) 4 (22.2%)  
N7 12 (9.4%) 0 (0.0%) 9 (10.6%) 3 (16.7%)  
POG 9640 8 (6.3%) 2 (8.0%) 5 (5.9%) 1 (5.6%)  
POG 9340/41/42 6 (4.7%) 0 (0.0%) 6 (7.1%) 0 (0.0%)  
POG 9341/42 6 (4.7%) 1 (4.0%) 5 (5.9%) 0 (0.0%)  
Other 12 (9.4%) 2 (8.0%) 7 (8.2%) 3 (16.7%)  
Unknown 6 (4.7%) 2 (8.0%) 4 (4.7%) 0 (0.0%)  
Treatment Protocol Status     0.66 
Enrolled On 42 (32.8%) 8 (32.0%) 30 (35.3%) 4 (22.2%)  
According To 69 (54.0%) 15 (60.0%) 42 (49.4%) 12 (66.7%)  
Unknown 17 (13.3%) 2 (8.0%) 13 (15.3%) 2 (22.2%)  
Number of Chemo Cycles* 6.8 (2.58) 6.5 (1.81) 6.8 (2.86) 7.1 (2.14) 0.49 
Radiation Received 124 (96.9%) 25 (100.0%) 81 (95.3%) 18 (100.0%) 0.77 
Days to Radiation from Diagnosis* 270.1 (101.64) 268.8 (76.20) 273.0 (108.49) 259.9 (108.53) 0.78 
Radiation Modality     0.07 
XRT Involved Field 92 (71.9%) 21 (84.0%) 61 (71.8%) 10 (55.6%)  
Proton Beam Therapy 5 (3.9%) 0 (0.0%) 1 (1.2%) 4 (22.2%)  
MIBG Therapy 2 (1.6%) 1 (4.0%) 1 (1.2%) 0 (0.0%)  
TBI 5 (3.9%) 1 (4.0%) 4 (4.7%) 0 (0.0%)  
XRT/TBI 9 (7.0%) 2 (8.0%) 6 (7.1%) 1 (5.6%)  
MIBG + XRT 2 (1.6%) 0 (0.0%) 1 (1.2%) 1 (5.6%)  
MIBG + TBI 1 (0.8%) 0 (0.0%) 1 (1.2%) 0 (0.0%)  
Unknown 12 (9.4%) 0 (0.0%) 10 (11.8%) 2 (11.1%)  
Table 1 (cont.) Patient Characteristics between Consolidated and Fragmented Care Groups 
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Days of Radiation* 13.7 (6.29) 14.7 (6.61) 12.5 (5.40) 17.4 (8.33) 0.09 
Receipt of Immunotherapy 43 (33.6%) 11 (44.0%) 22 (25.9%) 10 (55.6%) 0.03 
Distance to Diagnostic Facility      
Median (IQR) 36.2 (21.1-77.5) 78.1 (34.8-123.0) 30.8 (17.4-67.6) 35.6 (28.9-95.0) 0.002 
<25th Percentile 31 (24.2%) 1 (4.0%) 27 (31.8%) 3 (16.7%) 0.002 
25th – 75th Percentile 65 (50.8%) 11 (44.0%) 44 (51.8%) 10 (55.6%)  
>75th Percentile 32 (25.0%) 13 (52.0%) 14 (16.5%) 5 (27.8%)  
Distance to Chemo Facility      
Median (IQR) 38.5 (21.7-82.5) 78.1 (34.8-123.0) 30.8 (19.1-69.5) 35.6 (28.9-112.0) 0.004 
<25th Percentile 32 (25.0%) 1 (4.0%) 28 (32.9%) 3 (16.7%) 0.003 
25th – 75th Percentile 64 (50.0%) 12 (48.0%) 43 (50.6%) 9 (50.0%)  
>75th Percentile 32 (25.0%) 12 (48.0%) 14 (16.5%) 6 (33.3%)  
Distance to Surgical Facility      
Median (IQR) 42.0 (21.1-111.0) 78.1 (34.8-150.0) 31.1 (18.3-70.5) 68.8 (33.6-123.0) 0.002 
<25th Percentile 29 (22.7%) 1 (4.0%) 25 (29.4%) 3 (16.7%) 0.006 
25th – 75th Percentile 61 (47.7%) 12 (48.0%) 42 (49.4%) 7 (38.9%)  
>75th Percentile 30 (23.4%) 10 (40.0%) 13 (15.3%) 7 (38.9%)  
Distance to Radiation Facility      
Median (IQR) 96.8 (33.1-156.0) 78.1 (34.8-123.0) 108.5 (35.0-162.0) 78.5 (32.2-317.0) 0.73 
<25th Percentile 30 (23.4%) 6 (24.0%) 19 (22.4%) 5 (27.8%) 0.42 
25th – 75th Percentile 61 (47.7%) 16 (64.0%) 38 (44.7%) 7 (38.9%)  
>75th Percentile 30 (23.4%) 3 (12.0%) 21 (24.7%) 6 (33.3%)  
Distance to Duke (BMT Facility)      
Median (IQR) 126.0 (78.2-176.0) 78.1 (34.8-123.0) 134.0 (92.7-178.0) 136.0 (64.0-317.0) 0.006 
<25th Percentile 32 (25.0%) 13 (52.0%) 14 (16.5%) 5 (27.8%) 0.001 
25th – 75th Percentile 64 (50.0%) 10 (40.0%) 49 (57.6%) 5 (27.8%)  
>75th Percentile 32 (25.0%) 2 (8.0%) 22 (25.9%) 8 (44.4%)  
Distance to Immunotherapy Facility      
Median (IQR) 86.3 (32.7-155.0) 57.8 (28.5-121.0) 68.6 (26.9-125.0) 529.0 (121.0-567.0) 0.003 
<25th Percentile 10 (7.8%) 3 (12.0%) 7 (8.2%) 0 (0.0%) 0.008 
25th – 75th Percentile 22 (17.2%) 8 (32.0%) 11 (12.9%) 3 (16.7%)  
>75th Percentile 10 (7.8%) 0 (0.0%) 4 (4.7%) 6 (33.3%)  
Furthest Distance Traveled  
(Excluding BMT)** 
113.0 (40.8-224.5) 78.1 (34.8-123.0) 96.8 (32.3-174.0) 492.0 (193.0-567.0) 0.001 
ǂ Percentages are out of total population counts unless otherwise indicated and may not add up to 100% due to rounding or missing values 
* Values presented are Mean (SD) 
** Values presented are Median (IQR) 
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Minor Chemo Complications 117 (91.4%) 24 (96.0%) 77 (90.6%) 16 (88.9%) 1.00 
Major Chemo Complications 10 (7.8%) 4 (16.0%) 4 (4.7%) 2 (11.1%) 0.13 
      
Minor Surgical Complications 24 (18.8%) 6 (24.0%) 14 (16.5%) 4 (22.2%) 1.00 
Major Surgical Complications 12 (9.4%) 4 (16.0%) 6 (7.1%) 2 (11.1%) 1.00 
      
Minor Central Line Complications 98 (76.6%) 21 (84.0%) 64 (75.3%) 13 (72.2%) 0.86 
Major Central Line Complications 71 (55.5%) 20 (80.0%) 42 (49.4%) 9 (50.0%) 0.09 
      
Minor BMT Complications 128 (100%) 25 (100.0%) 85 (100%) 18 (100.0%) ---- 
Major BMT Complications 15 (11.7%) 7 (28.0%) 6 (7.1%) 2 (11.1%) 0.02 
      
Minor Radiation Complications 14 (10.9%) 4 (16.0%) 5 (5.9%) 5 (27.8%) 0.28 
Major Radiation Complications 2 (1.6%) 1 (4.0%) 0 (0.0%) 1 (5.6%) 0.22 
      
Minor Immunotherapy Complications 26 (20.3%) 8 (32.0%) 15 (17.6%) 3 (16.7%) 1.00 
Major Immunotherapy Complications 2 (1.6%) 0 (0.0%) 2 (2.4%) 0 (0.0%) 1.00 
      
Thrombotic Complications 32 (25.0%) 4 (16.0%) 24 (28.2%) 4 (22.2%) 0.56 
      
Any Major Complication 81 (63.3%) 22 (88.0%) 49 (57.6%) 10 (55.6%) 0.01 
      
Any Major Complication  
(Excluding Central Lines) 
31 (24.2%) 11 (44.0%) 17 (20.0%) 3 (16.7%) 0.04 
* Major complications defined as those requiring invasive intervention or resulting in serious disability or death 
** Complications requiring removal/replacement of a central line were considered major 
 
 
Table 3: Univariate and Multivariate Models for Overall Survival (OS) 

















Age at diagnosis (years) 127 3.0 (1.0 - 4.0) 1.048 (0.953 - 1.153) 0.33 0.33     
Number of central line infections 103 1.0 (1.0 - 2.0) 1.207 (0.954 - 1.529) 0.12 0.12     
Number of central lines 115 3.0 (2.0 - 5.0) 1.052 (0.860 - 1.289) 0.62 0.62     
Care Fragmentation     0.10    0.21 
Coordinated Care 25 9 (36.0%) Reference    Reference   
Fragmented Care (2 Locations) 84 40 (47.6%) 1.116 (0.539 - 2.312) 0.77   0.855 (0.389 - 1.879) 0.70  
Fragmented Care (>2 Locations) 18 12 (66.7%) 2.173 (0.912 - 5.179) 0.08   1.539 (0.607 - 3.901) 0.36  
Year of Diagnosis     0.002    0.024 
1990-1999 41 32 (78.0%) Reference    Reference   
2000-2009 50 20 (40.0%) 0.409 (0.231 - 0.723) 0.002   0.472 (0.263 - 0.847) 0.012  
2010-2017 36 9 (25.0%) 0.378 (0.178 - 0.799) 0.011   0.480 (0.220 - 1.045) 0.06  
Histological Favorability     0.17     
Favorable 2 2 (100.0%) Reference       
Unfavorable 71 24 (33.8%) 0.362 (0.085 - 1.538) 0.17      
Surgery before Chemotherapy     0.51     
No 97 41 (42.3%) Reference       
Yes 21 11 (52.4%) 1.250 (0.639 - 2.448) 0.51      
Chemotherapy Protocol     0.014     
Other 35 17 (48.6%) Reference       
ANBL0532 28 11 (39.3%) 1.090 (0.502 - 2.366) 0.83      
COG A3973 30 9 (30.0%) 0.474 (0.208 - 1.079) 0.08      
CCG 3891 10 8 (80.0%) 2.098 (0.893 - 4.929) 0.09      
N7 12 6 (50.0%) 0.816 (0.317 - 2.096) 0.67      
POG 9341/2 12 10 (83.3%) 2.089 (0.944 - 4.624) 0.07      
Chemotherapy On/Off Protocol     0.043     
No 67 24 (35.8%) Reference       
Yes 41 23 (56.1%) 1.810 (1.019 – 3.218) 0.043      
Home Distance to Chemotherapy Facility     0.96     
25-75th percentile 63 30 (47.6%) Reference       
<25th percentile 32 15 (46.9%) 1.007 (0.536 - 1.891) 0.98      
>75th percentile 32 16 (50.0%) 1.085 (0.587 - 2.007) 0.79      
Home Distance to Duke (BMT Facility)     0.002    0.043 
25-75th percentile 63 24 (38.1%) Reference    Reference   
<25th percentile 32 13 (40.6%) 1.026 (0.509 - 2.067) 0.94   1.005 (0.481 - 2.098) 0.99  
>75th percentile 32 24 (75.0%) 2.612 (1.477 - 4.618) <0.001   2.060 (1.135 - 3.741) 0.018  
Immunotherapy     0.09     
No 82 48 (58.5%) Reference       
Yes 43 12 (27.9%) 0.573 (0.303 - 1.085) 0.09      
*N (%) of patients who died in each category. For continuous variables, median (Q1 – Q3) are presented of patients who died. 
**Values may not align exactly with Table 1 due to missing survival or covariate information for some patients. 
Table 4: Univariate and Multivariate Models for Relapse 

















Age at diagnosis (years) 123 3.0 (1.0 - 4.0) 1.032 (0.939 - 1.134) 0.51 0.51     
Number of central line infections 100 1.0 (1.0 - 2.0) 1.158 (0.911 - 1.472) 0.23 0.23     
Number of central lines 112 3.0 (2.0 - 5.0) 1.073 (0.883 - 1.304) 0.48 0.48     
Care Fragmentation     0.031    0.10 
Coordinated Care 25 9 (36.0%) Reference    Reference   
Fragmented Care (2 Locations) 80 38 (47.5%) 1.209 (0.582 - 2.511) 0.61   0.939 (0.434 - 2.029) 0.87  
Fragmented Care (>2 Locations) 18 14 (77.8%) 2.583 (1.113 - 5.990) 0.027   1.847 (0.758 - 4.497) 0.18  
Year of Diagnosis     0.007    0.05 
1990-1999 39 30 (76.9%) Reference    Reference   
2000-2009 48 20 (41.7%) 0.466 (0.262 - 0.830) 0.010   0.524 (0.289 - 0.949) 0.033  
2010-2017 36 11 (30.6%) 0.395 (0.196 - 0.798) 0.010   0.493 (0.238 - 1.024) 0.06  
Histological Favorability     0.003     
Favorable 2 2 (100.0%) Reference       
Unfavorable 68 23 (33.8%) 0.090 (0.018 - 0.437) 0.003      
Surgery before Chemotherapy     0.48     
No 94 42 (44.7%) Reference       
Yes 21 11 (52.4%) 1.274 (0.652 - 2.489) 0.48      
Chemotherapy Protocol     0.06     
Other 35 18 (51.4%) Reference       
ANBL0532 28 12 (42.9%) 1.006 (0.478 - 2.119) 0.99      
COG A3973 28 9 (32.1%) 0.536 (0.238 - 1.209) 0.13      
CCG 3891 9 7 (77.8%) 2.152 (0.887 - 5.222) 0.09      
N7 12 6 (50.0%) 0.805 (0.316 - 2.051) 0.65      
POG 9341/2 11 9 (81.8%) 1.847 (0.820 - 4.158) 0.14      
Chemotherapy On/Off Protocol     0.05     
No 65 25 (38.5%) Reference       
Yes 39 22 (56.4%) 1.774 (0.997 – 3.158) 0.05      
Home Distance to Chemotherapy Facility     0.83     
<25th percentile 30 14 (46.7%) Reference       
25-75th percentile 61 30 (49.2%) 0.948 (0.498 - 1.806) 0.87      
>75th percentile 32 17 (53.1%) 1.142 (0.561 - 2.324) 0.71      
Home Distance to Duke (BMT Facility)     0.003    0.09 
<25th percentile 32 13 (40.6%) Reference    Reference   
25-75th percentile 62 27 (43.5%) 1.226 (0.618 - 2.434) 0.56   0.845 (0.414 - 1.722) 0.64  
>75th percentile 29 21 (72.4%) 2.876 (1.397 - 5.922) 0.004   1.798 (0.983 - 3.289) 0.06  
Immunotherapy     0.10     
No 78 45 (57.7%) Reference       
Yes 43 15 (34.9%) 0.612 (0.339 - 1.104) 0.10      
*N (%) of patients who died in each category. For continuous variables, median (Q1 – Q3) are presented of patients who died. 
**Values may not align exactly with Table 1 due to missing relapse or covariate information for some patients. 


























(B) Kaplan-Meier for Relapse-Free Survival  
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Appendix A: Living Remotely from Pediatric Cancer Treatment and the Effect on Survival 
and Treatment-Related Outcomes: A Systematic Review 
 
Introduction 
 Delivering safe and effective pediatric cancer treatment requires multiple, complex 
therapeutic modalities and collaboration between many providers across myriad clinical 
specialties. To ensure best practice, the American Academy of Pediatrics (AAP) has established 
guidelines for pediatric cancer centers in an effort to centralize and coordinate care for both 
patients and providers. These recommendations include that pediatric cancer centers must be 
equipped with a board-certified pediatric oncologist; appropriately qualified medical and surgical 
pediatric subspecialists; access to a pediatric ICU, hemodialysis, and up-to-date imaging and 
radiotherapy; and the capability to deliver multidisciplinary care.1 Additionally, the Children’s 
Oncology Group (COG) has enrolled many such specialized institutions in an effort to more 
effectively enroll and treat pediatric cancer patients on appropriate clinical trials.2 Presently, over 
90% of pediatric cancer patients are treated at COG-member institutions.2 These coordinated 
efforts and therapeutic innovations have led to survival rates over 80% for many pediatric cancer 
patients.3 
 However, accessing treatment at COG-member institutions or similarly-equipped centers 
may prove challenging for many patients and their families. While the COG has significantly 
expanded its reach since its inception, the 194 US institutions are located predominately in urban 
and metropolitan areas.2 However, approximately 20% of the US population lives in rural areas 
often far removed such population centers.4 As a result, many families may face a significant 




The financial and psychosocial burden associated with increased travel for pediatric 
cancer patients has been well documented. Families who live far removed from appropriate 
treatment frequently pay more in travel costs and accommodations, often must take excessive 
time off work, and may utilize savings to afford treatment.5-10 The excess financial burden 
associated with travel also poses detriment to many families’ ability to cope with their situation. 
Additionally, receiving treatment far away means that patients and their immediate families are 
often separated from home support, feel a lack of coordination and trust in local providers, must 
take on increased responsibility during the treatment process, and face feelings of isolation.11-13  
Regarding survival and treatment-related outcomes, there have been myriad studies 
examining the association of distance to survival and/or treatment-related outcomes in adult 
healthcare. A recent systematic review by Kelly et al. demonstrated that increased travel distance 
to health services may be associated with poorer outcomes for adults.14 Additionally, for adult 
cancer patients, some studies have shown that those who live further from major treatment 
centers may present with later stage disease, receive different treatments than their closer 
counterparts, and experience worsened survival outcomes.15-17 However, comparably sparse 
literature has examined the association between travel burden and similar outcomes for pediatric 
cancer patients. 
Accordingly, the aim of this systematic review is to synthesize the published literature 
describing the effect of travel burden on survival and treatment-related outcomes for pediatric 
cancer patients and families living far removed from appropriate treatment. We hypothesized 
that increased distance would be associated with decreased survival, access to appropriate care, 






 We searched PubMed, EMBASE, and Scopus electronic databases through March 22, 
2019. Basic search criteria included English-language studies with terms relevant to pediatric 
cancer care and distance/travel to treatment. We reviewed all available citations published after 
1986, which is the aforementioned date of the first AAP published guidelines for pediatric cancer 
centers and treatment. A full search strategy is detailed in Figure A-1. 
 
Selection Criteria 
 To be eligible for inclusion, studies needed to be (1) full-text, peer-reviewed articles, (2) 
focus on pediatric cancer patients, and (3) describe a relationship between distance/travel to 
treatment and overall survival or treatment-related outcomes such as treatments received, place 
of care, disease stage, and clinical trial participation. Studies examining urban vs rural residence 
as a proxy for distance were also included. Studies were excluded if they did not examine 
geographic relation to treatment as an exposure or if comparisons between geographic regions 
(i.e. Northeast vs. Southeast) was the measure of comparison. Additionally, studies examining 
the experiences of families traveling to other countries for advanced treatment were excluded. 
An age of 21 years was chosen as a cutoff for pediatric patients as many of these patients may 
still be treated at children’s cancer facilities. Studies examining patients aged >21 years were 
included if appropriate subset analysis for children aged <21 years was conducted. Importantly, 
however, any studies that self-identified as focusing on a teen and young adult (TYA) population 
were excluded due to wide variation in care and practice patterns for young adults (such as 
variable treatment at adult vs pediatric centers), unless appropriate subset analysis was 
conducted. Finally, those studies focusing only on financial or psychosocial outcomes were 
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excluded because of the influence of myriad factors aside from travel distance. A full, detailed 
table of inclusion and exclusion criteria can be found in Table A-1. 
 
Data Collection Process 
 Following the deletion of duplicate articles, all articles derived from the three databases 
were independently screened by two reviewers (AT and LO) using CovidenceTM software using 
criteria summarized in Table A-1. The full-text articles of titles and abstracts marked as 
potentially relevant were reviewed again to confirm eligibility using the same criteria. Any 
disagreement was resolved by consensus-based decision.  
 
Data Extraction 
 Data extraction was performed using a standardized form to ensure collection of each 
variable of interest. Each study had relevant information extracted independently by two 
reviewers (AT and LO) with any discrepancies resolved by consensus in order to ensure quality 
of extraction. Variables of interest included the study location, year of publication, population 
studied, study design, type of cancer (if stratified), measurement of distance, potential 
socioeconomic and clinical confounders, outcomes measured, statistical methods used, and 
results with regard to measured outcomes. 
 
Summary Measures and Results Synthesis 
 Overall study characteristics were first reported by study design, study population, type 
of cancer analyzed, and by distance measure utilized. Results were then reported and 
summarized by their relationship of distance/travel to either survival outcomes or treatment 
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related outcomes. Due to the heterogeneity in study design and measured outcomes, meta-
analysis was not performed. Descriptive statistics and univariate results were not presented when 
multivariate analysis with adjustment was conducted, and results were presented with reporting 
of overall conclusions and effect. 
 
Analysis of Quality and Potential Bias 
 Each study was individually assessed for risk of bias using the Newcastle-Ottawa Quality 
Assessment Scale (NOQAS), modified slightly to fit different study designs. Two authors (AT 
and LO) reviewed each study and results were compared. All discrepancies were resolved by 
consensus-based decision. Risk of bias across similar studies was analyzed from the perspective 
of potential publication bias, consistency of findings, and overall strength of association. 
 
Results 
Study Selection and Characteristics 
 Following the removal of duplicates, the literature search identified 7,607 articles eligible 
for title and abstract screening. Of these, 106 studies were assessed during full-text review. 
Ultimately, 24 studies were included in the final analysis.18-41 The most common reasons for 
exclusion included a focus primarily on young adults, no analysis based on distance, or an 
incorrect outcome or study design. Of the included studies, 20 were retrospective cohort 
studies18-22,24,25,28,29,31-41, two were prospective cohort studies23,30, one was cross-sectional26, and 
one was a case-control study27.  
In terms of population, most focused on pediatric cancers overall. However, specific 
cancers analyzed included any CNS tumors20,26,39, any non-CNS solid tumors21,26,36, 
leukemias23,26,28,35, medulloblastoma31,33, retinoblastoma24, and melanoma29. Tools and methods 
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used to measure distance varied significantly, including use of the Great Circles Algorithm18,32,36, 
distance between midpoints of home address and treating facility19,22,38, and road driving distance 
using either ArcGIS or Google Maps.19,20,29,35,39 The distance traveled was categorized variably 
and ranged from 0-5 miles19 to 300+ miles.38 Rurality of residence was used as a proxy for 
geographic access (either in place of or in addition to mileage) in 9 studies.24,25,26,28,31,33,35,36,41 
Three studies included analysis of adults or young adults but also included appropriate subset 
analysis for children.18,25,39 Most studies were rated as good, with those receiving fair or poor 
ratings due largely to lack of appropriate multivariate adjustment. These characteristics, 
outcomes, and quality assessments can be seen in Tables A2 – A4.  
 
Survival Outcomes 
 Of the 24 included studies, 12 included survival as an outcome 
measurement.20,21,23,28,29,31,33,35,37,39,41 All but 2 used a measure of overall survival (OS) as the 
outcome. Those other two focused on retinoblastoma-specific mortality and event-free survival, 
respectively.24.28 In 5 of 12 studies, distance was not included in a multivariate survival 
analysis.28,29,31,37,39  Ultimately, no studies found an association between travel distance and 
survival, in either univariate or multivariate analysis. Covariates commonly controlled for 
included age, sex, race, and disease stage when available. However, three studies demonstrated 
worsened survival outcomes for those living in rural counties as compared to urban counties 
closer to treatment centers.24,31,41 Tai et al. conducted a population-based study only examining 
cancer-specific mortality rates for adolescents and did not analyze factors associated with 





 Of the 24 included studies, 19 examined outcomes related to treatment or place of care.18-
22,25-27,30-32,34,36,38,39 Specific outcomes measured included the likelihood of receiving care at 
specialized pediatric cancer centers18,19,22,39,40, likelihood of advanced stage presentation at 
diagnosis20,21,29,41, clinical trial participation25,34, likelihood of receiving proton beam therapy or 
hematopoietic stem cell transplantation (HSCT)31,32,36,38, length of stay for febrile neutropenia 
patients19, use of emergency transportation26, likelihood of same-day cancellation27, and waiting 
times.30 Travel distance >40 miles was associated with a decreased likelihood of receiving care at 
specialized pediatric cancer centers, but living 6-20 miles away was associated with an increased 
likelihood compared to 0-5 miles away.19 Increasing travel distance was also associated with 
more care received at local facilities than specialized ones located further away.40 There was no 
demonstrated association between travel distance and disease stage at first presentation or 
diagnosis. One of the two studies examining clinical trial enrollment found that enrollment 
decreased with every 100km away from specialized treatment34, but the other found no 
association.25 Results regarding the effect of distance on receipt of particular therapies were 
inconsistent, with 2 of 4 studies demonstrating increased odds of receiving proton beam therapy 
(HSCT)36,38, one showing decreased follow-up after proton therapy for those living >300km 
away32, and the fourth demonstrating that distance had no significant effect on treatment.31 
Finally, increasing travel distance/time was associated with greater need for emergency 







 To our knowledge, this is the first systematic review synthesizing and compiling studies 
that examined the potential effect of travel distance and/or rurality on both survival and 
treatment-related outcomes for pediatric cancer patients. Across all 24 included studies, there 
was no consistent association between travel distance/rurality and measured clinical outcomes. 
Some studies demonstrated that those from rural settings had decreased survival compared to 
their urban or metropolitan counterparts24,31,41, but these results were tenuous at best given 
minimal multivariate analysis or adjustment for relevant covariates. More studies demonstrated 
an association between travel distance/rurality and select outcomes such as place of care, clinical 
trial participation, and receipt of particular complex treatment modalities. However, the direction 
of effect was inconsistent, with several studies unexpectedly demonstrating increased likelihood 
of receiving proton therapy, HSCT, or shorter hospital stays when diagnosed with febrile 
neutropenia for those living further away.19,36,38 Together, these studies suggest that those living 
furthest away from treatment are not at increased risk for poor outcomes and that other 
socioeconomic and patient characteristics are more significant for ensuring best treatment 
practices and improving survival. 
 Effectively treating pediatric cancer frequently requires utilization of multiple, complex 
therapeutic modalities, including surgery and HSCT for select cancers. For adult cancer patients, 
an abundance of literature demonstrates that survival outcomes are improved at high-volume 
centers in major metropolitan areas.42-47 Additionally, Lidsky et al. found that pancreatic patients 
undergoing pancreaticoduodenectomy at high-volume centers, even after accounting for the 
increased travel burden to get there, had superior survival outcomes relative to those traveling a 
shorter distance to low-volume centers.48 Similarly, it is well-established that high survival rates 
for pediatric cancer patients can largely be attributed to receipt of care at specialized institutions. 
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These results and the findings of this review suggest that seeking care at such places is likely to 
result in improved survival outcomes for pediatric cancer patients, even if it means overcoming a 
significant travel burden.  
 Studies examining the effect of travel on treatment-related outcomes had more variable 
results. Those that had to travel further were not at increased likelihood of having advanced stage 
disease or experiencing increased waiting times at specialized facilities, indicating that disease 
progression is likely a more protracted process and that rural patients need not worry about 
receiving delayed or inferior care. These results run counter to findings for adult oncology 
patients that rural patients are more likely to experience delays throughout the treatment 
process.49 While encouraging for pediatric cancer patients, Klein-Getlink et al. conducted their 
study in Canada, where treatment times and processes may be different than in the US due to a 
national health system. Moreover, Fluchel et al. demonstrated that patients with increased travel 
times or from rural areas utilized emergency transportation at higher rates.26 This may result 
from a need for rapid and effective transportation in the event of complications or emergencies 
occurring at home. Families living far removed from specialized centers must often take on 
increased responsibility for home care and management of factors such as central lines, creating 
a nidus for increased complications.50  
 Only one of two studies demonstrated decreased clinical trial enrollment with increased 
travel burden, and that studied was conducted in Canada.34 Much of pediatric cancer treatment in 
the US occurs through clinical trial-directed therapy, despite variable reported outcomes.2,51 As 
such, it is essential to ensure that pediatric cancer patients have equitable access to clinical trials. 
That same study found that physician preference was a major reason for trial non-enrollment.34 
Physicians may be more reluctant to enroll patients on clinical trials with strict guidelines when 
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regular travel to treatment may pose a significant barrier. Paradoxically, 2 studies also found that 
living further away from centers equipped to deliver proton therapy or HSCT was associated 
with increased likelihood of receiving those treatments.36,38 However, in the study by Shen et al., 
that effect was only present when further stratifying by income. Several other studies have 
shown either no effect of distance or place of residence or have demonstrated decreased 
likelihood of receiving HSCT for those living further away.52-54 Truong et al. suggest that 
patients living closer to specialized treatment facilities may be offered more experimental and 
investigative therapies than HSCT.38 However, the overall lack of association between distance 
and clinical trial enrollment, which are often experimental in nature, would suggest the opposite.  
 Due to the rarity and complexity of pediatric cancer, traversing large distances to 
specialized institutions for treatment may be unavoidable for many patients and families. As 
such, the results of this review are encouraging in demonstrating no effect of travel distance on 
various outcomes overall. Given the well-documented financial and psychosocial burden 
associated with increased travel for pediatric cancer patients and families, patients may choose to 
receive some elements of care at local facilities and avoid unnecessary travel where possible. In 
these circumstances, it is essential to ensure that local, unspecialized facilities and providers are 
adequately equipped to provide high-quality treatment. This might be accomplished through 
increased investment in pediatric cancer care and potentially by use of telemedicine modalities to 
share with rural facilities expertise that is otherwise concentrated at select, specialized centers.55 
 While somewhat minimal and inconsistent, the results that were significant in this study 
were primarily found with comparisons of rurality rather than actual travel distance. We elected 
to include rurality comparisons as a distance proxy because of the urban locations of many 
specialized pediatric cancer centers. However, rurality status is an imperfect proxy because that 
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status does not truly incorporate the distance that patients might travel to treatment. Moreover, 
the methods used to determine or classify rurality was inconsistent across studies, with some 
using census continuums and others self-stratifying based on populations of individual areas. The 
discrepancy between significant results by rurality but not by travel distance may be reflective of 
additional socioeconomic factors relevant to those from rural areas. Some studies adjusted for 
such socioeconomic factors well, but not all did so or utilized multivariate analysis. Therefore, 
any conclusions for those from rural areas must be taken lightly with regard to evaluations of the 
effects of travel distance to treatment. 
 Importantly, we chose to restrict our review to studies examining pediatric and adolescent 
patients aged <21 and excluded any studies examining older young adults. Increasingly, the 
adolescent and young adult population (AYA), sometimes defined as ages 15-29 and others as 
ages 15-39, is recognized as a separate patient population for cancer treatment. 
Recommendations and practice guidelines for this group differ significantly from those for 
pediatric cancer patients. While excluded from our review because of these differences, a 
growing body of literature has recognized disparities in access to and treatment at pediatric 
cancer centers associated with increasing age and travel distance for AYA patients.56-63 These 
discrepancies may result from older adolescents increasingly being treated at adult centers closer 
to home. Comprehensively reviewing the literature for AYA patients is outside the scope of this 
review, but a similar systematic review of the effects of distance and geographic relation to 
treatment for this patient population may be warranted. 
 This review has several important limitations. First, our search strategy and inclusion 
criteria may have missed relevant articles. However, the searches of multiple databases and 
independent review by 2 authors using the same criteria minimized this risk. Second, we elected 
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to include studies from all countries in which the COG operates as treatment for pediatric 
cancers is likely to be more uniform and standardized. We also chose a cutoff date of 1986 
following the first AAP pediatric cancer center recommendations, even though those 
recommendations may not be relevant in other countries. The inclusion of studies outside the US 
may minimize generalizability due to differences in health systems and transportation, but our 
focus on survival and treatment-related outcomes rather than financial burden or psychosocial 
outcomes minimized this potential discrepancy. Third, the included body of literature had 
limitations. While most studies were retrospective cohort studies, there was significant 
heterogeneity in study design, distance measurement, and confounder adjustment, limiting direct 
comparison or possible meta-analysis. Third, no studies tracked the cumulative distance traveled 
by patients during the entire course of treatment. This may be more indicative of potential travel 
burden but is challenging to impossible to measure with retrospective studies.  
 
Conclusion 
 This review has synthesized findings about the effects of travel distance to treatment 
and/or rural residence for pediatric cancer patients with regard to survival and treatment-related 
outcomes. Several studies demonstrated worsened survival outcomes for those living in more 
rural areas and decreased clinical trial enrollment, greater likelihood of receiving proton therapy 
and HSCT, and shorter hospital stays for febrile neutropenia patients associated with increased 
travel distance. However, results were inconsistent and varied overall, leading to a final 
conclusion that living further away from treatment centers does not confer poorer outcomes. 
These findings are valuable for rural patients and families who must overcome a significant 
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Table A1: Study Inclusion and Exclusion Criteria 




• Children (<21 years) 
• Cancer diagnosis 
• Adults 
• TYA-specific population 
• Other non-cancer diagnoses 
Exposure 
 
• Distance/travel to treatment or hospitals • Survivorship care 









• Clinical or treatment-related outcomes 
(i.e. treatment adherence, place of care, 
disease stage, complications, etc) 
• Incidence/prevalence of cancer 
• Financial outcomes 
• Psychosocial outcomes 
Timing 
 
• 1986 - Present • Prior to 1986 
Setting(s) 
 
• Clinical/hospital settings 
• US, Canada, Europe, New Zealand, 
Australia 
• Community Settings 
• Other Countries 
Study Design(s) 
 
• Prospective and retrospective cohort, 
case-control, cross-sectional 
• Editorials, position/opinion pieces, 









Figure A1: Pubmed, EMBASE, and Scopus Search Strategy 
Database (including vendor/platform): PubMed  
Set #  Results 
1 "Pediatrics"[Major] OR pediatric[tiab] OR pediatrics[tiab] OR 
paediatric[tiab] OR paediatrics[tiab] OR juvenile[tiab] OR 
"Child"[Major] OR child[tiab] OR children[tiab] OR childhood[tiab] OR 
teenage[tiab] OR adolescent[tiab] OR adolescents[tiab] 
1,615,336 
2 "Neoplasms"[Mesh] OR neoplasms[tiab] OR neoplasm[tiab] OR 
cancer[tiab] OR cancers[tiab] OR malignant[tiab] OR malignancy[tiab] 
OR malignancies[tiab] OR oncology[tiab] OR oncologic[tiab] OR 
tumor[tiab] OR tumors[tiab] OR tumours[tiab] OR tumour[tiab] 
3,977,881 
3 Travel[mesh] OR travel[tiab] OR traveling[tiab] OR travelling[tiab] OR 
traveled[tiab] OR travelled[tiab] OR distance[tiab] OR distances[tiab] 
OR distantly[tiab] OR location[tiab] OR locations[tiab] OR 
located[tiab] OR remote[tiab] OR remotely[tiab] OR rural[tiab] OR 
geography[tiab] OR geographic[tiab] OR geographical[tiab] OR 
geographically[tiab] 
1,253,170 
4 treatment[tiab] OR treatments[tiab] OR cancer care[tiab] OR 
hospital[tiab] OR hospitals[tiab] OR center[tiab] OR centers[tiab] OR 
facility[tiab] OR facilities[tiab] OR site[tiab] OR sites[tiab] OR 
clinic[tiab] OR clinics[tiab] 
6,553,853 
5  1 AND 2 AND 3 AND 4 5,286 
6 NOT (Editorial[ptyp] OR Letter[ptyp] OR Comment[ptyp]) 5,272 
 
 
Database (including vendor/platform): Embase (Elsevier) 
 
Set #  Results 
1 'pediatrics'/mj OR pediatric:ti,ab OR pediatrics:ti,ab OR 
paediatric:ti,ab OR paediatrics:ti,ab OR juvenile:ti,ab OR 'child'/mj OR 
child:ti,ab OR children:ti,ab OR childhood:ti,ab OR teenage:ti,ab OR 
adolescent:ti,ab OR adolescents:ti,ab 
2,219,992 
2 'neoplasm'/exp OR neoplasms:ti,ab OR neoplasm:ti,ab OR 
cancer:ti,ab OR cancers:ti,ab OR malignant:ti,ab OR malignancy:ti,ab 
OR malignancies:ti,ab OR oncology:ti,ab OR oncologic:ti,ab OR 
tumor:ti,ab OR tumors:ti,ab OR tumours:ti,ab OR tumour:ti,ab 
5,523,734 
3 'travel'/exp OR travel:ti,ab OR traveling:ti,ab OR travelling:ti,ab OR 
traveled:ti,ab OR travelled:ti,ab OR distance:ti,ab OR distances:ti,ab 
OR distantly:ti,ab OR location:ti,ab OR locations:ti,ab OR located:ti,ab 
OR remote:ti,ab OR remotely:ti,ab OR rural:ti,ab OR geography:ti,ab 
OR geographic:ti,ab OR geographical:ti,ab OR geographically:ti,ab 
1,537,214 
4 treatment:ti,ab OR treatments:ti,ab OR 'cancer care':ti,ab OR 
hospital:ti,ab OR hospitals:ti,ab OR center:ti,ab OR centers:ti,ab OR 
facility:ti,ab OR facilities:ti,ab OR site:ti,ab OR sites:ti,ab OR 
clinic:ti,ab OR clinics:ti,ab 
9,149,450 
5  1 AND 2 AND 3 AND 4 10,462 
6 AND ([article]/lim OR [article in press]/lim OR [erratum]/lim OR 






Database (including vendor/platform): Scopus (Elsevier) 
Set #  Results 
1 TITLE-ABS ( pediatric  OR  pediatrics  OR  paediatric  OR  paediatrics  
OR  juvenile  OR  child  OR  children  OR  childhood  OR  teenage  OR  
adolescent  OR  adolescents ) 
2,316,228 
2 TITLE-ABS ( neoplasms  OR  neoplasm  OR  cancer  OR  cancers  OR  
malignant  OR  malignancy  OR  malignancies  OR  oncology  OR  
oncologic  OR  tumor  OR  tumors  OR  tumours  OR  tumour ) 
3,350,005 
3 TITLE-ABS ( travel  OR  traveling  OR  travelling  OR  traveled  OR  
travelled  OR  distance  OR  distances  OR  distantly  OR  location  OR  
locations  OR  located  OR  remote  OR  remotely  OR  rural  OR  
geography  OR  geographic  OR  geographical  OR  geographically ) 
1,537,214 
4 TITLE-ABS(treatment OR treatments OR "cancer care" OR hospital 
OR hospitals OR center OR centers OR facility OR facilities OR site 
OR sites OR clinic OR clinics) 
11,152,836 
5  1 AND 2 AND 3 AND 4 10,462 
6 AND  ( EXCLUDE ( DOCTYPE ,  "no" )  OR  EXCLUDE ( DOCTYPE ,  "le" )  






Figure A2: PRISMA Flow Diagram 
  Number of articles 
identified for screening:  
16,485 
Total number of studies screened: 
7,607 
Number of full text articles 
identified for eligibility: 106 
Number of studies included in 
Systematic Review: 24 
Number of duplicates removed:  
8,877 
Number of studies excluded :  
7,501 
Number of full-text articles excluded: 82 
- TYA or Adult Population: 17 
- Primarily non-cancer focus (>80%): 3 
- No Distance/Residence Analysis: 13 
- Incorrect Outcome: 15  
- Incorrect Study Design: 15 
- Geographic region comparison: 6 
- Palliative/Terminal Care: 6 
- Survivorship Care: 1 
- Incorrect Year: 4 
- Unable to access full-text: 1 













































Pts 0-18 2,421 CNS Solid Tumors N n/a n/a 






 State Clinical 
Database 
 













units in Greece 










Pts Not Specified 1,456 
Retinoblastoma 
(Rb) N n/a n/a 










Pts 0-18 1541 Primary ALL N n/a n/a 







Database Pts 0-18 235 Melanoma N n/a n/a 









Pts 0-19 783 Medulloblastoma (Mb) N n/a n/a 












Categories Results Covariates Interpretation 
Austin et al. 
(2016) 







Adjusted OR (95% CI) 
Reference 
0.97 (0.78 – 1.20) 
0.91 (0.76 – 1.11) 
Age, sex, race, SES 
quintile, behavior of 
tumor, disease stage 
No effect of 
distance 
Austin et al. 
(2015) 







Adjusted OR (95% CI) 
Reference 
1.1 (1.0 - 1.3) 
1.1 (1.0 - 1.3) 
Age, sex, race, SES 
quintile, year of 
diagnosis, disease stage 





Not Specified Overall Survival (OS) <50 km 
50+ km 
 
Adjusted Death Rate Ratio (95% CI) 
Reference 
1.77 (0.93 - 3.37) 
 
Age, gender, maternal 
schooling, marital 
status, number of 
children, day care, WBC 
count, ALL type 




Rural vs Urban 
Rural-urban continuum 








Cox-Proportional Hazard Estimate 
Reference 
 
β = 0.9337, p=0.0198 
 
SEER stage, 







Gupta et al. 
(2014) 
Rural vs Urban 
Rurality defined by Ontario 
Index based on zip code 
Short vs Long Distance 










Hazard Ratio (95% CI)* 
Reference 
1.15 (0.80 – 1.64) 
 
Reference 
1.05 (0.79 – 1.38) 
No Multivariate Analysis No effect of distance 
Hamilton et al. 
(2016) 







Hazard Ratio (95% CI)* 
Reference 
0.6 (0.2 - 1.9) 
0.7 (0.2 - 2.0) 
No Multivariate Analysis No effect of distance 
Kopecky et al. 






















survival in rural 
counties 
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records Pts 0-14 50 
Medulloblastoma 
(Mb) N n/a n/a 


















AML N n/a n/a 











Pts 15-19 N/A Any N n/a n/a 




























Pts 0-14 6756 Any N n/a n/a 












Categories Results Covariates Interpretation 
Moschovi  
et al. 





Adjusted Death Rate Ratio (95% CI) 
Reference 
3.43 (0.91 - 12.07) 
Chemotherapy, sex, age, 


























Adjusted Death Rate Ratio (95% CI) 
ALL 
Reference 
1.16 (0.74 -  1.81) 
1.08 (0.69 -  1.70) 
 
Reference 
1.29 (0.80 -  2.10) 




0.52 (0.22 -  1.24) 
1.08 (0.48 -  2.46) 
 
Reference 
0.84 (0.34 -  2.07) 
1.06 (0.48 - 2.31) 
Age, sex, marital status, 
socioprofessional category, 
maternal age at birth, 
maternal education, # of 
children, ALL subtype 
No effect of distance 







Zone A  
(0-10 miles) 
 
Zone B  
(10-25 miles) 
 
Zone C  
(25-50 miles) 
 
Zone D  
(> 50 miles) 
 
Total Deaths 






3.05 (p<0.05 compared to Zone A) 
 
1396 
2.94 (p<0.05 compared to Zone A) 
 
1697 
2.88 (p<0.05 compared to Zone A) 
 
N/A Highest mortality closest to COG centers 























Grade II CNS 





































Pgradient = 0.009 
Sex, age group, stage 
Worse survival for those 
living further removed 
for leukemia, but only 
remote for all cancers 
Table A2 (cont.): Survival Studies Characteristics and Results 
 
  




























Pts 0-24 1,355 Any Y 15-19 321 




























Any N n/a n/a 









Pts 0-18 2,421 CNS Solid Tumors N n/a n/a 






































Pts Any 51,024 Any Y Children (<15) 317 
Table A3: Treatment-Related Studies Characteristics and Results 
ǂ Febrile Neutropenia 
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Table A3 (cont.): Treatment-Related Studies Characteristics and Results 
 
Study Distance Measurement Method 
Outcomes 




Great Circles Algorithm 
(Shortest spherical distance 
between home & hospital 
zip codes) 
Likelihood of 







Only 15-19 Subgroup Analysis 
Square Root of Distance from Center 
Adjusted OR (95% CI) 
0.93 (0.86 - 1.02) 
Cancer Type, Age (for 
15-19) 
No effect of distance by 
any age group 
Alvarez et al. 
(2017) 
Distance between midpoints 
of home and hospital zip 
Likelihood of 








Adjusted OR (95% CI) 
Reference 
1.52 (1.15 - 2.00) 
1.43 (1.07 - 1.92) 
0.91 (0.71 - 1.17) 
0.77 (0.63 - 0.94) 
Age, Sex, Insurance 




likelihood with living 6-
10 and 11-20 and 
slightly decreased with 
living >40 
Alvarez et al. 
(2017) 
Distance between 
midpoints of home and 
hospital zip 
Length of Stay >8 








Adjusted OR (95% CI) 
Reference 
0.98 (0.92 - 1.05) 
0.85 (0.78 - 0.92) 
0.87 (0.81 - 0.95) 
0.87 (0.80 - 0.94) 
Institution Type, Age, 
Sex, Insurance Payer, 




Slightly less likelihood 
with increasing distance 
Austin et al. 
(2016) 








Adjusted OR (95% CI) 
Reference 
1.15 (0.85 – 1.56) 
0.91 (0.69 – 1.21) 
Age, sex, race, SES 
quintile, behavior of 
tumor, disease stage 
No effect of distance 
Austin et al. 
(2015) 








Adjusted OR (95% CI) 
Reference 
1.1 (0.9 - 1.3) 
1.0 (0.9 - 1.2) 
Age, sex, race, SES 
quintile, year of 
diagnosis, disease 
stage 





midpoints of home and 
hospital zip 
Likelihood of 








Adjusted OR (95% CI) 
Reference 
0.70 (0.66 - 0.75) 
1.21 (1.12 - 1.32) 
 1.49 (1.36 - 1.63) 






No effect of distance 





Not Specified Clinical Trial Participation 
<7.22 miles 
7.22 - 22.63 miles 





Adjusted HR (95% CI) 
Reference 
0.70 (0.31 - 1.61) 
0.64 (0.27 - 1.52) 
1.22 (0.52 - 2.88) 
 
Reference 
1.06 (0.57 - 1.96) 









































































































Pts 0-19 783 Medulloblastoma (Mb) N n/a n/a 














Pts 0-21 333 Any N n/a n/a 
Table A3 (cont.): Treatment-Related Studies Characteristics and Results 
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Table A3 (cont.): Treatment-Related Studies Characteristics and Results 
 
Study Distance Measurement Method 
Outcomes 
Measured Distance Categories Results Covariates Interpretation 
Fluchel et al. 
(2014) 
Rural vs Urban; Classified by 
commuting area codes 
based on zip 
 
MapQuest calculated travel 
times; 
1hr based on neutropenic 
fever referral 
2hr based on surrounding 
metro 
Emergency 








Rural vs Urban 
Travel time >1hr vs < 1hr 
Travel time >2hr vs <2hr 
 
Rural vs Urban 
Travel time >1hr vs < 1hr 
Travel time >2hr vs <2hr 
Rate Ratio (95% CI) 
1.6 (0.9 - 2.8) 
1.6 (1.1 - 2.6) 
1.6 (1.0 - 2.5) 
 
5.9 (2.7 - 13.1) 
3.8 (1.7 - 8.5) 






quit work, patient 
held back in school 
Increasing 
distance/travel time 






























Adjusted HR (95% CI) 
Reference 
1.4 (0.6 - 3.0) 
1.8 (0.8 - 4.1) 
Sex, age, race, dx year, 




Postal codes converted to 
latitude and longitude 
Aerial distances between 





to First Contact 
 

















Adjusted OR for Waiting Longest 
Quartile Vs Three Shortest 












Age, sex, diagnosis, 
region of residence, 
type of initial 
healthcare 
consultation 

















Analysis No effect of distance 
Lawell et al. 
(2019) 
Great Circles Algorithm 
(Shortest spherical distance 






Within 75 mile radius 
Outside 75 mile radius 
Linear Regression Parameter 
Estimate (95% CI) 
Reference 
β = -0.53 (-0.81 - -0.26) 
Trial co-enrollment, 
treatment delay, 






































Pts 0-14 9204 Any N n/a n/a 









Pts 0-21 12,101 Solid Tumors N n/a n/a 




















































Pts 0-14 6756 Any N n/a n/a 
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Table A3 (cont.): Treatment-Related Studies Characteristics and Results 
  
Study Distance Measurement Method 
Outcomes 
Measured Distance Categories Results Covariates Interpretation 
Pole et al. 
(2017) Not Specified 
Clinical Trial 
Participation Per 100 Km 
Adjusted OR (95% CI) 
0.96 (0.94 - 0.98) 




Less enrollment with 
increasing distance 
Shen et al. 
(2017) 
Great Circles Algorithm 
(Shortest spherical distance 
between home zip and 
hospital zip); 
Rurality defined by 
population size, degree of 
urbanization, and adjacency 










>100 miles, median 
income <$63,000 
>100 miles, median 
income >$63,000 









Age, primary tumor 
site, histology, stage, 
primary insurance, 
median income, 
education, location of 
facility (all treatment 
or some elsewhere) 
Effect of distance only 
when factoring in 
income; Effect no longer 
present with subset 
analysis of treatment at 
the reporting facility vs 
elsewhere  
Truong et al. 
(2019) 
Distance between 
midpoints of home and 
hospital zip 
Likelihood of 




200 - 300 km 
>300 km 
Adjusted OR (95% CI) 
Reference 
0.79 (0.47  -1.32) 
0.76 (0.35 - 1.65) 
1.84 (1.17 - 2.91) 




eriod, relapse before HSCT, 
HSCT center diagnosis, 









ArcGIS straight-line distance 
to nearest treating center 
Likelihood of 






Adjusted OR (95% CI) 
Reference 
0.90 (0.38 to 2.09) 
Age group (0-14, 15-
21), race, SES, 
Insurance status 
No effect of distance 
Yeager et al. 
(2006) 
45 of Ohio counties 
grouped by increasing 
distance from Franklin 
county, where the 
academic childrens and 
adult center is located 
Likelihood of 
Receipt of Care 











Cochran-Armitage Test for % 
Treated at Each Facility Type 
p-value 
Local vs Peds/AA 
1 (4.2%) vs 23 (85.8%) 
10 (32.3%) vs 21 (67.7%) 
 12 (32.4%) vs 25 (67.6%) 
11 (30.6%) vs 25 (69.4%) 




associated with more 





based on road distance to 








Stage 1/2 vs Stage 3/4** 
41.0% vs 44.3% 
38.3% vs 48.5% 
44.3% vs 45.2% 
p=0.323 
N/A No effect of remoteness 
**Only Descriptive Analysis Conducted 
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Table A4: Quality Assessment – Cohort Studies 
 
    Selection Comparability   
Study Study Type Representativeness Control Selection 
Ascertainment 
of Exposure 
Outcome of Interest 
Not Present at Start Comparability of Cohorts by Design/Analysis 









Records  Yes  Study controls for diagnosis or stage  









Records  Yes  
Study controls for diagnosis or stage  
Study controls for sex, age, insurance, race, income 









Records   Yes  
Study controls for sex, age, race, SES, year, and malignant 
behavior  









Records  Yes  Study controls for sex, age, race, SES, year  









Records  Yes  Study controls for sex, age, race, insurance, income  
Charalampopoulou 









Records  Yes  
Study controls for WBC count  








Records  Yes  
Study controls for diagnosis or stage  
Study controls for race, % college graduates, income  









Records  Yes  Study controls for age, sex, deprivation, cancer site  









Records  Yes  Only univariate analysis for exposure of interest  









Records  Yes  
Study controls for diagnosis or stage  
Study controls for sex, age, race, diagnosis year, SES  









Records  Yes  
Study controls for diagnosis or stage  
Study controls for sex and age  









Records  Yes  Only univariate analysis for exposure of interest 
Lawell et al. 
(2019) 
Retrospective 




Records  Yes  
Study controls for follow-up method  
Study controls for trial enrollment, delays, insurance 









Records  Yes  
Study controls for sex, age, chemotherapy, and maternal 
education  









Records  Yes  
Study controls for diagnosis or stage 
Study controls for sex, age, race, time period, income 









Interview  Yes  




Table A4 (cont.): Quality Assessment – Cohort Studies 
 
  
  Outcome Number of Stars Grade 
Study Study Type Assessment Follow-Up Timing Adequacy of Follow-Up 
  
Albritton et al. 
(2007) 
Retrospective 
Cohort Record Linkage  Yes  No Description 7 Good 
Alvarez et al. 
(2017) 
Retrospective 
Cohort Record Linkage  Yes  No Description 8 Good 
Austin et al. 
(2016) 
Retrospective 
Cohort Record Linkage  Yes  No Description 7 Good 
Austin et al. 
(2015) 
Retrospective 
Cohort Record Linkage  Yes  No Description 7 Good 
Chamberlain et al.  
(2014) 
Retrospective 
Cohort Record Linkage  Yes  No Description 7 Good 
Charalampopoulou 









Cohort Record Linkage  No No Description 5 Poor 
Donnelly et al. 
(2017) 
Retrospective 
Cohort Record Linkage  Yes  No Description 7 Good 
Gupta et al. 
(2014) 
Retrospective 
Cohort Record Linkage  Yes  No Description 6 Poor 
Hamilton et al. 
(2016) 
Retrospective 
Cohort Record Linkage  Yes  <20% loss  9 Good 
Klein-Geltink et al. 
(2005) 
Prospective 
Cohort Record Linkage  Yes  No Description 8 Good 
Kopecky et al. 
(2017) 
Retrospective 
Cohort Record Linkage  Yes  No Description 6 Poor 
Lawell et al. 
(2019) 
Retrospective 
Cohort Record Linkage  Yes  Complete  8 Good 
Moschovi et al. 
(2007) 
Retrospective 
Cohort Record Linkage  Yes  No Description 7 Good 
Pole et al. 
(2017) 
Retrospective 
Cohort Record Linkage  Yes  Complete  9 Good 





Assessment Yes  Complete  8 Good 
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Table A4 (cont.): Quality Assessment – Cohort Studies 
Table A4 (cont.): Quality Assessment – Cohort Evaluation 
Table A4 (cont.): Quality Assessment – Cohort Studies 
 
 
  Outcome Number of Stars Grade 
Study Study Type Assessment Follow-Up Timing 
Adequacy of 
Follow-Up   
Shen et al. 
(2017) Retrospective Cohort Record Linkage  Yes No Description 8 Good 
Tai et al. 
(2018) Retrospective Cohort Record Linkage  Yes No Description 6 Fair 
Truong et al. 
(2019) Retrospective Cohort Record Linkage  Yes No Description 8 Good 
Wolfson et al. 
(2014) Retrospective Cohort Record Linkage  Yes No Description 7 Good 
Yeager et al. 
(2006) Retrospective Cohort Record Linkage  Yes No Description 6 Poor 
Youlden et al. 
(2011) Retrospective Cohort Record Linkage  Yes No Description 7 Good 
 
  
   Selection Comparability 




Outcome of Interest 
Not Present at Start Comparability of Cohorts by Design/Analysis 










Study controls for diagnosis or stage  
Study controls for age, site, insurance, income, facility 
location 








Other No Study controls for diagnosis or stage Study controls for sex, race 










Study controls for diagnosis or stage 
Study controls for WBC count, sex, age, race, income, 
relapse, diagnosis year 









Records Yes Study controls for age, race, SES, insurance 









Records Yes No adjustment 









Records Yes Study controls for sex and age 
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Table A5: Quality Assessment – Case Control Studies 





 Selection Comparability Outcome Number of Stars (Max=10) 























No Description of 
Non-Responders 
Study controls for stage 
Study controls for age, race, 
education 




    
Selection Comparability Exposure Number of Stars (Max = 8) 























Control Yes Yes Yes 
Same 
Population No adjustment 
Medical 
Record Yes N/A 6 
